Focused On-demand Library for Exostosin-1

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q16394

UPID:
EXT1_HUMAN

ALTERNATIVE NAMES:
Glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase; Multiple exostoses protein 1; Putative tumor suppressor protein EXT1

ALTERNATIVE UPACC:
Q16394; B2R7V2; Q9BVI9

BACKGROUND:
The protein Exostosin-1, with alternative names such as Multiple exostoses protein 1, functions as a glycosyltransferase for heparan-sulfate synthesis. It forms a more active complex with EXT2 and is implicated in tumor suppression. Its activity is crucial for the release of molecules like SDCBP and CD63 from exosomes.

THERAPEUTIC SIGNIFICANCE:
Dysfunction in Exostosin-1 is associated with diseases like hereditary multiple exostoses 1, tricho-rhino-phalangeal syndrome 2, and chondrosarcoma, highlighting its importance in bone growth and cancer prevention. Exploring Exostosin-1's role offers a promising avenue for developing therapies for these genetic and malignant conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.